Abaloparatide Linked to Lower Fracture Risk in Women With Osteoporosis, Obesity
A post hoc analysis of the phase 3 ACTIVE trial of abaloparatide for fracture prevention in postmenopausal women was presented at ENVISION, the 2021 AACE Annual Meeting.